Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 24,500 employees deliver annual net sales of around €10 billion. The company is listed on NYSE Euronext.
The focus of DSM Chemical Technology R&D B.V. (department Innovative Synthesis) lies on the development of sustainable and economic processes towards a broad range of these life science and material science products. Biocatalysis is an indispensable technology to achieve these routes and processes. Current focus of the mid and long term strategic research is on Oxidoreductases and Lyases including Monooxygenases and carbon-carbon lyases.
key personnel: Rob Meier
“The research for this work has received funding from the European Union (EU) project ROBOX (grant agreement n° 635734) under EU’s Horizon 2020 Programme Research and Innovation actions H2020-LEIT BIO-2014-1”